NOVO HOLDINGS | In this opinion piece timed to the World Economic Forum Davos 2020, Kasim Kutay, Chief Executive Director of Novo Holdings, says the drought of new treatments for drug-resistant infections will not end anytime soon, unless policy-makers fix the broken antibiotics market. Right now, drug companies are hesitant to invest in superbug research, since any resulting treatment would only be used in limited, emergency cases. Researchers stand little chance of recouping their costs, much less of earning a profit. Biotech firms and investors like Novo won’t be able to fight superbugs without government assistance.